90 related articles for article (PubMed ID: 19820365)
1. Rising cancer antigen 125 level and the type and timing of treatment for recurrent ovarian cancer: a clinical dilemma, but what would women do?
Harrison JD; Juraskova I; Anderson C; Nattress K; Beale P; Lopez AL; Carter J
Int J Gynecol Cancer; 2009 Aug; 19(6):1037-46. PubMed ID: 19820365
[TBL] [Abstract][Full Text] [Related]
2. "The booklet helped me not to panic": a pilot of a decision aid for asymptomatic women with ovarian cancer and with rising CA-125 levels.
Anderson C; Carter J; Nattress K; Beale P; Philp S; Harrison J; Juraskova I
Int J Gynecol Cancer; 2011 May; 21(4):737-43. PubMed ID: 21412158
[TBL] [Abstract][Full Text] [Related]
3. [Diagnosis and treatment of recurrent epithelial ovarian carcinoma].
Wu XF; Chen HZ; Han DF
Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):664-6. PubMed ID: 14728851
[TBL] [Abstract][Full Text] [Related]
4. [Epithelial ovarian cancer: what is the consensus in 1995?].
Chevallier B; Dessogne P
Bull Cancer; 1995 Nov; 82(11):923-8. PubMed ID: 8535018
[TBL] [Abstract][Full Text] [Related]
5. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls.
Díaz-Padilla I; Razak AR; Minig L; Bernardini MQ; María Del Campo J
Clin Transl Oncol; 2012 Jan; 14(1):15-20. PubMed ID: 22262714
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.
Lukácskó I; Hernádi Z; Sápy T; Borsos A
Acta Chir Hung; 1997; 36(1-4):213-4. PubMed ID: 9408350
[TBL] [Abstract][Full Text] [Related]
8. Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer.
Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Franklin J; Friedlander M; Andrews L
Psychooncology; 2005 Apr; 14(4):249-61. PubMed ID: 15386771
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.
Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N
Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541
[TBL] [Abstract][Full Text] [Related]
10. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer.
Menzel C; Döbert N; Hamscho N; Zaplatnikov K; Vasvatekis S; Matic V; Wördehoff N; Grünwald F
Strahlenther Onkol; 2004 Aug; 180(8):497-501. PubMed ID: 15292970
[TBL] [Abstract][Full Text] [Related]
11. Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument.
Elit LM; Levine MN; Gafni A; Whelan TJ; Doig G; Streiner DL; Rosen B
Gynecol Oncol; 1996 Sep; 62(3):329-35. PubMed ID: 8812525
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and Cost Analysis of Surveillance Strategies After Initial Treatment for Women With Recurrent Ovarian Cancer.
Alexander VM; Gordon AN; Howard DH; Khanna N
Int J Gynecol Cancer; 2017 Sep; 27(7):1333-1342. PubMed ID: 28692633
[TBL] [Abstract][Full Text] [Related]
13. The impact of epithelial ovarian cancer diagnosis on women's life: a qualitative study.
Mangone L; Mandato VD; Gandolfi R; Tromellini C; Abrate M
Eur J Gynaecol Oncol; 2014; 35(1):32-8. PubMed ID: 24654458
[TBL] [Abstract][Full Text] [Related]
14. The choice is yours? How women with ovarian cancer make sense of treatment choices.
Ziebland S; Evans J; McPherson A
Patient Educ Couns; 2006 Sep; 62(3):361-7. PubMed ID: 16876377
[TBL] [Abstract][Full Text] [Related]
15. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease.
Bast RC
Cancer; 2010 Jun; 116(12):2850-3. PubMed ID: 20564390
[No Abstract] [Full Text] [Related]
16. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
17. How to follow-up patients with epithelial ovarian cancer.
Miller RE; Rustin GJ
Curr Opin Oncol; 2010 Sep; 22(5):498-502. PubMed ID: 20498597
[TBL] [Abstract][Full Text] [Related]
18. Information needs and decisional preferences among women with ovarian cancer.
Stewart DE; Wong F; Cheung AM; Dancey J; Meana M; Cameron JI; McAndrews MP; Bunston T; Murphy J; Rosen B
Gynecol Oncol; 2000 Jun; 77(3):357-61. PubMed ID: 10831342
[TBL] [Abstract][Full Text] [Related]
19. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV).
Rohr I; Alavi S; Richter R; Keller M; Chekerov R; Oskay-Özcelik G; Heinrich M; Taskiran C; Joly F; Berger R; du Bois A; Gornjec A; Vergote I; Achimas-Cadariu P; Lorusso D; Maenpaa J; Sehouli J
Int J Gynecol Cancer; 2020 Apr; 30(4):509-514. PubMed ID: 32139438
[TBL] [Abstract][Full Text] [Related]
20. Playing the waiting game ... the asymptomatic patient with recurrent ovarian cancer detected only by rising Ca125 levels.
Fleming LW
Scott Med J; 2001 Jun; 46(3):81-3. PubMed ID: 11501326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
